Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Radin

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Pharmaceuticals (Basel, Switzerland)|March 27, 2025
AMPA Receptor Modulation in the Treatment of High-Grade Glioma: Translating Good Science into Better OutcomesDaniel P Radin
Anticancer Research|July 26, 2017
BDNF: An Oncogene or Tumor Suppressor?Daniel P Radin, Parth Patel
European Journal of Pharmacology|April 17, 2016
Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancersDaniel P Radin, Parth Patel
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 15, 2017
A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitorsDaniel P Radin, Parth Patel
International Journal of Molecular Sciences|November 14, 2020
Interactions between Tumor Cells, Neurons, and Microglia in the Glioma MicroenvironmentDaniel P Radin, Stella E Tsirka
Pharmacological Reports : PR|November 1, 2019
PINK1 depletion sensitizes non-small cell lung cancer to glycolytic inhibitor 3-bromopyruvate: Involvement of ROS and mitophagyKatherine Dai, Daniel P Radin, Donna Leonardi
Neural Regeneration Research|October 16, 2020
Deciphering the dual role and prognostic potential of PINK1 across cancer typesKatherine Dai, Daniel P Radin, Donna Leonardi
Anticancer Research|December 27, 2017
Oncolytic Properties of Ampakines <i>In Vitro</i>Daniel P Radin, Richard Purcell, Arnold S Lippa
Frontiers in Immunology|October 7, 2022
From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade gliomaGregory T Smith, Daniel P Radin, Stella E Tsirka
Anticancer Research|December 27, 2017
Our ACE in the HOLE: Justifying the Use of Angiotensin-converting Enzyme Inhibitors as Adjuvants to Standard ChemotherapyDaniel P Radin, Austin Krebs, Arman Maqsudlu, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Pharmaceuticals (Basel, Switzerland)|March 27, 2025
AMPA Receptor Modulation in the Treatment of High-Grade Glioma: Translating Good Science into Better OutcomesDaniel P Radin
Anticancer Research|July 26, 2017
BDNF: An Oncogene or Tumor Suppressor?Daniel P Radin, Parth Patel
European Journal of Pharmacology|April 17, 2016
Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancersDaniel P Radin, Parth Patel
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 15, 2017
A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitorsDaniel P Radin, Parth Patel
International Journal of Molecular Sciences|November 14, 2020
Interactions between Tumor Cells, Neurons, and Microglia in the Glioma MicroenvironmentDaniel P Radin, Stella E Tsirka
Pharmacological Reports : PR|November 1, 2019
PINK1 depletion sensitizes non-small cell lung cancer to glycolytic inhibitor 3-bromopyruvate: Involvement of ROS and mitophagyKatherine Dai, Daniel P Radin, Donna Leonardi
Neural Regeneration Research|October 16, 2020
Deciphering the dual role and prognostic potential of PINK1 across cancer typesKatherine Dai, Daniel P Radin, Donna Leonardi
Anticancer Research|December 27, 2017
Oncolytic Properties of Ampakines <i>In Vitro</i>Daniel P Radin, Richard Purcell, Arnold S Lippa
Frontiers in Immunology|October 7, 2022
From protein-protein interactions to immune modulation: Therapeutic prospects of targeting Neuropilin-1 in high-grade gliomaGregory T Smith, Daniel P Radin, Stella E Tsirka
Anticancer Research|December 27, 2017
Our ACE in the HOLE: Justifying the Use of Angiotensin-converting Enzyme Inhibitors as Adjuvants to Standard ChemotherapyDaniel P Radin, Austin Krebs, Arman Maqsudlu, et al.
Pageof 3